Zhejiang Garden Bio-Chemical High-Tech Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
July 30, 2021 at 02:30 pm IST
Share
Zhejiang Garden Bio-chemical High-tech Co., Ltd. announced earnings results for the half year ended June 30, 2021. For the half year, the company announced sales was CNY 349.638 million compared to CNY 345.184 million a year ago. Operating income was CNY 274.490 million compared to CNY 187.031 million a year ago. Net income was CNY 235.577 million compared to CNY 162.535 million a year ago. Basic earnings per share from continuing operations was CNY 0.43 compared to CNY 0.34 a year ago.
Zhejiang Garden Biopharmaceutical Co Ltd, formerly Zhejiang Garden Bio-chemical High-tech Co Ltd, is a China-based company mainly engaged in the research, development, production and sales of vitamin D3 upstream and downstream products. The Company's vitamin products mainly include lanolin cholesterol, food and pharmaceutical grade vitamin D3, 25-hydroxyvitamin D3 and others. The Company also focuses on the research and development, production and sales of high-tech barrier preparations in the fields of cardiovascular, nervous system and other chronic diseases. The other products of the Company include Levofloxacin Tablets, Doxofylline Injection, Lipoic Acid Injection, Escitalopram Oxalate Tablets and others.
ZHEJIANG GARDEN BIOPHARMACEUTICAL CO.,LTD. 
